雜志介紹

European Neuropsychopharmacology雜志介紹

《European Neuropsychopharmacology》是一本以English為主的未開放獲取國際優秀期刊，中文名稱歐洲神經精神藥理學，本刊主要出版、報道醫學-CLINICAL NEUROLOGY領域的研究動態以及在該領域取得的各方面的經驗和科研成果，介紹該領域有關本專業的最新進展，探討行業發展的思路和方法，以促進學術信息交流，提高行業發展。該刊已被國際權威數據庫SCIE收錄，為該領域相關學科的發展起到了良好的推動作用，也得到了本專業人員的廣泛認可。該刊最新影響因子為6.1，最新CiteScore 指數為10.3。

本刊近期中國學者發表的論文主要有：

• Effect of psychotropics on the risk of COVID-19 in middle-aged and older adults

  Author: Ma, Yue; Li, Shu; Yang, Hongxi; Zhang, Yuan; Li, Huiping; Xu, Fusheng; Hou, Yabing; Zhang, Xinyu; Wang, Yaogang

• Association between the loudness dependence of auditory evoked potential, serotonergic neurotransmission and treatment outcome in patients with depression

  Author: Ip, Cheng-Teng; Ganz, Melanie; Ozenne, Brice; Olbrich, Sebastian; Beliveau, Vincent; Dam, Vibeke H.; Kohler-Forsberg, Kristin; Jorgensen, Martin B.; Frokjaer, Vibe G.; Knudsen, Gitte M.

• Inflammatory disequilibrium and lateral ventricular enlargement in treatment-resistant schizophrenia

  Author: Chen, Wenjin; Gou, Mengzhuang; Wang, Leilei; Li, Na; Li, Wei; Tong, Jinghui; Zhou, Yanfang; Xie, Ting; Yu, Ting; Feng, Wei; Li, Yanli; Chen, Song; Tian, Baopeng; Tan, Shuping; Wang, Zhiren; Pan, Shujuan; Luo, Xingguang; Zhang, Ping; Huang, Junchao; Tian, Li; Li, Chiang -Shan R.; Tan, Yunlong

• Functional asymmetry of thalamocortical networks in subjects at ultra-high risk for psychosis and first-episode schizophrenia

  Author: Furong Zhu, Yi Liu, Feng Liu, Ru Yang, Huabing Li, Jindong Chen, David N. Kennedy, Jingping Zhao, Wenbin Guo

英文介紹

European Neuropsychopharmacology雜志英文介紹

European Neuropsychopharmacology is the official publication of the European College of Neuropsychopharmacology (ECNP). In accordance with the mission of the College, the journal focuses on clinical and basic science contributions that advance our understanding of brain function and human behaviour and enable translation into improved treatments and enhanced public health impact in psychiatry. Recent years have been characterized by exciting advances in basic knowledge and available experimental techniques in neuroscience and genomics. However, clinical translation of these findings has not been as rapid. The journal aims to narrow this gap by promoting findings that are expected to have a major impact on both our understanding of the biological bases of mental disorders and the development and improvement of treatments, ideally paving the way for prevention and recovery.